Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

SPHERO-NASH

Financiado

A novel NASH model for target and drug candidate identification

NASH is the progressive form of NAFLD that underlies the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The global prevalence of NASH is estimated at 1 billion individuals. NASH is a major cause of death, now th... ver más

28/02/2025

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-05

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

2 Participantes

100.00K€ | Lider

HEPAPREDICT AB

50.00K€ | Participante

Proyectos interesantes

CPP2021-008633 Modelos 3D innovadores derivados de tejido hepático humano p... 395K€ Cerrado

EIN2020-112209 ANALISIS METABOLICO EN TIEMPO REAL DE MODELOS DE CULTIVO DE... 10K€ Cerrado

MIP-DILI Mechanism-Based Integrated Systems for the Prediction of Dru... 32M€ Cerrado

SAF2017-85877-R INVESTIGACION TRASLACIONAL EN ESTEATOHEPATITIS NO ALCOHOLICA... 182K€ Cerrado

PDC2021-121010-I00 DESARROLLO DE FARMACOS PRIMEROS EN SU CLASE PARA TRATAR LA E... 150K€ Cerrado

NASHTARGET Validation of a new drug target in non-alcoholic steatohepat... 150K€ Cerrado

Últimas noticias

01-12-2024: REDES En las últimas 48 horas el Organismo REDES ha otorgado 1337 concesiones

01-12-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

01-12-2024: AEI En las últimas 48 horas el Organismo AEI ha otorgado 23 concesiones

Duración del proyecto: 20 meses Fecha Inicio: 2023-06-05
Fecha Fin: 2025-02-28

Líder del proyecto

KAROLINSKA INSTITUTET

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto NASH is the progressive form of NAFLD that underlies the development of fibrosis, cirrhosis, and hepatocellular carcinoma. The global prevalence of NASH is estimated at 1 billion individuals. NASH is a major cause of death, now the major reason for liver transplantations and the disease is an important cause of hepatocellular cancer (HCC). Currently, there are no FDA-approved drug therapies available. Within the ERC project Hepaspher, a new liver model was developed in which human hepatocytes and non-parenchymal cells are grown in a 3D spheroid structure that phenotypically closely resembles human liver in vivo with respect to transcriptome, proteome, and metabolome for up to 35 days. This model has proven to be of valuable use for the development and treatment of liver diseases such as steatosis, cholestasis, hepatitis, insulin resistance, and fibrosis. In the SPHERO-NASH project, we focus on a more complex system whereby both inducers and mechanisms of NASH formation, drug-induced inhibition of NASH as well as studies of extracellular matrix (ECM) degradation including collagens and the role of ECM degradation control in the development and treatment of NASH can be studied. For this purpose HTS based screening in the SPHERO-NASH spheroid system will take place utilizing both siRNA target libraries and chemical inhibition libraries at HepaPredict AB with a proposed delivery of novel compounds/targets that can be further processed in drug developmental projects. We propose to commercialize the SPHERO-NASH model itself but also to commercialize targets and compounds found by siRNA and compound screening that regulate NASH formation and degradation. We aim to assess and demonstrate the commercial value to the pharmaceutical industry by building a strong knowledge transfer strategy. The SPHERO-NASH model thus has great fundamental and commercial potential in NASH drug discovery and development.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores